Ara 290 Cibinetida

Descripción

Cibinetide (ARA 290 or PHBSP) is a synthetic 11-amino acid peptide engineered from the helix B surface domain of erythropoietin (EPO), designed to retain EPO’s tissue-protective and anti-inflammatory properties while eliminating its erythropoietic (red blood cell-producing) effects. It selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and CD131 (β-common receptor), triggering downstream pathways that suppress pro-inflammatory cytokines, reduce oxidative stress, promote tissue repair, and modulate immune responses without stimulating hematopoiesis. Preclinical and clinical studies demonstrate Cibinetide’s ability to reverse small nerve fiber loss, regenerate corneal nerve fibers, alleviate neuropathic pain, improve metabolic parameters (e.g., HbA1c and insulin sensitivity in type 2 diabetes models), and confer neuroprotection in conditions involving inflammation or nerve damage. Phase 2 clinical trials have shown significant benefits in patients with sarcoidosis-associated small fiber neuropathy (increased corneal nerve fiber density, reduced neuropathic symptoms, and pain relief) and type 2 diabetes (improved metabolic control and neuropathy symptoms), with effects mediated by anti-inflammatory actions, enhanced endothelial function, and tissue regeneration. In wellness and regenerative medicine contexts, Cibinetide is explored via subcutaneous injection (typical research doses 1–4 mg daily or several times weekly) for potential support in chronic pain, autoimmune/inflammatory conditions, diabetic complications, sarcoidosis, and recovery from nerve injury or stress. Users and early trial data report reduced inflammation, better pain management, improved energy, and enhanced nerve health over weeks to months. While generally well-tolerated with mild side effects (injection-site reactions, transient fatigue, or headache), Cibinetide is not FDA-approved for any therapeutic, pain relief, neuropathy treatment, or wellness use as of 2026—it remains investigational, with ongoing research and no large-scale approval-level trials completed for broad indications. Evidence stems from preclinical models, phase 2 human studies, and clinical observations rather than definitive phase 3 data. Potential risks include unknown long-term effects, interactions with immune-modulating drugs, or rare hypersensitivity reactions. Cibinetide should only be used under strict medical supervision with proper monitoring (e.g., inflammatory markers, nerve function assessments) and sourced from reputable compounding pharmacies or research channels. Always consult a qualified healthcare provider experienced in peptide or inflammatory therapies to evaluate suitability, determine dosing, and integrate it into a comprehensive plan including lifestyle interventions. Cibinetide offers a targeted approach to innate repair and inflammation modulation when benefits outweigh risks.